Tuberculosis: From Pathophysiology to Pharmacologic Management — A Comprehensive Review

In a recent outbreak at a long‑term care facility, 12 residents developed active pulmonary tuberculosis within 3 weeks, underscoring how quickly Mycobacterium tuberculosis can spread in vulnerable populations. Clinicians must therefore master the nuances of TB treatment, from first‑line agents to drug‑resistant variants, to prevent morbidity, mortality, and further transmission. This article provides an in‑depth review of TB’s epidemiology, pharmacologic principles, and practical management strategies for pharmacy and medical students.

Introduction and Background

Tuberculosis (TB) has plagued humanity since antiquity, with skeletal lesions resembling the disease described in the 15th‑century Chinese text Shennong Bencao Jing. Despite advances in public health, TB remains the leading infectious killer worldwide, with an estimated 10.6 million new cases and 1.6 million deaths in 2022 alone. The disease is caused by Mycobacterium tuberculosis, a slow‑growing, acid‑fast bacillus that predominantly targets the lungs but can disseminate to any organ system.

TB’s epidemiology is shaped by socioeconomic factors, HIV co‑infection, and the emergence of drug‑resistant strains. The World Health Organization’s End TB Strategy aims for a 90% reduction in TB deaths and a 80% reduction in incidence by 2030, yet progress is uneven across regions. Clinically, TB presents as a spectrum from latent infection to active disease, with symptoms ranging from chronic cough and hemoptysis to constitutional malaise and weight loss. The pathophysiology involves a robust cell‑mediated immune response, with granuloma formation attempting to contain the bacilli. However, the organism’s unique cell wall rich in mycolic acids and a propensity for intracellular survival allow it to evade host defenses and resist many antibiotics.

Pharmacologic management of TB relies on a combination of drugs that target distinct bacterial processes: Isoniazid (INH) inhibits mycolic acid synthesis; Rifampin (RIF) blocks RNA polymerase; Ethambutol (EMB) interferes with arabinogalactan assembly; Pyrazinamide (PZA) disrupts membrane transport; and Streptomycin (SM) binds the 30S ribosomal subunit. These agents are typically used in multi‑drug regimens to prevent resistance and achieve synergistic bactericidal activity.

Mechanism of Action

Isoniazid (INH)

INH is a prodrug activated by the bacterial catalase‑peroxidase enzyme KatG. Once activated, it forms a complex with NAD+, which then inhibits the enoyl‑ACP reductase (InhA) enzyme, a critical step in mycolic acid synthesis. The resulting depletion of mycolic acids compromises the integrity of the mycobacterial cell wall, leading to cell lysis. The activation step is a key point of resistance; mutations in katG reduce prodrug activation, while mutations in inhA confer low‑level resistance by altering the target site.

Rifampin (RIF)

RIF binds to the β‑subunit of bacterial DNA‑dependent RNA polymerase, blocking the initiation of transcription. By preventing the synthesis of essential proteins, RIF exerts a potent bactericidal effect. RIF is also a strong inducer of hepatic cytochrome P450 enzymes, notably CYP3A4, which can accelerate the metabolism of concomitant drugs and reduce their efficacy.

Ethambutol (EMB)

EMB interferes with the polymerization of arabinogalactan, an essential component of the mycobacterial cell wall. It binds to the arabinosyl transferase enzyme, inhibiting the synthesis of the arabinogalactan–mycolic acid complex. EMB is primarily bacteriostatic, but its role in preventing the emergence of resistance during combination therapy is critical.

Pyrazinamide (PZA)

PZA is a weak acid that is converted by the bacterial pyrazinamidase (PZase) to pyrazinoic acid (POA). POA disrupts membrane transport and enzyme activity, particularly at acidic pH, thereby exerting bactericidal activity against dormant bacilli within macrophages. Resistance arises from mutations in the pncA gene encoding PZase, reducing activation of the drug.

Streptomycin (SM)

SM binds the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis. It is bactericidal but has limited use today due to the availability of more effective oral agents and its significant ototoxicity and nephrotoxicity.

Clinical Pharmacology

Pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of first‑line TB drugs vary widely, influencing dosing schedules and monitoring strategies. The following table summarizes key PK/PD parameters for the core agents used in standard therapy.

Pharmacodynamic considerations include the time‑dependent killing of INH and RIF, whereas EMB and PZA exhibit concentration‑dependent killing. The bactericidal activity of RIF is augmented when combined with INH, and the presence of PZA shortens the duration of therapy by targeting dormant bacilli. Monitoring of drug levels is not routinely required for most patients, but therapeutic drug monitoring may be indicated in cases of malabsorption, hepatic impairment, or suspected resistance.

Therapeutic Applications

• Standard therapy for drug‑sensitive pulmonary TB: 2 months of HRZE (Isoniazid, Rifampin, Pyrazinamide, Ethambutol) followed by 4 months of HR.

• Latent TB infection (LTBI): Isoniazid 300 mg daily for 9 months or Rifampin 600 mg daily for 4 months.

• Multidrug‑resistant TB (MDR‑TB): Regimens incorporating fluoroquinolones (Levofloxacin, Moxifloxacin), injectable agents (Amikacin, Capreomycin), and newer oral drugs (Bedaquiline, Delamanid).

• Extensively drug‑resistant TB (XDR‑TB): Intensive phase with Bedaquiline, linezolid, and clofazimine, followed by continuation phase with levofloxacin and amoxicillin‑clavulanate.

• Special populations:

  1. Pediatrics: Weight‑based dosing; INH 10–15 mg/kg; RIF 10–15 mg/kg; EMB 15–30 mg/kg; PZA 20–25 mg/kg.

  2. Geriatrics: Monitor for hepatic dysfunction; consider lower INH dose in fast acetylators.

  3. Renal impairment: INH and RIF are safe; EMB dose adjustment for CrCl <30 mL/min.

  4. Hepatic impairment: Avoid PZA and RIF in severe disease; monitor LFTs closely.

  5. Pregnancy: INH, RIF, and EMB are category B; PZA is category C; therapy is essential to prevent vertical transmission.

Adverse Effects and Safety

The safety profile of first‑line TB drugs is complex, with overlapping toxicities that necessitate vigilant monitoring. The following table lists common adverse effects with approximate incidence rates, serious warnings, and key drug interactions.

Monitoring parameters include baseline and periodic liver function tests (ALT, AST, bilirubin), visual acuity checks for EMB, serum uric acid for PZA, and renal function for SM. Contraindications are contraindicated in patients with severe hepatic disease (for INH, RIF, PZA), pre‑existing optic neuropathy (for EMB), or significant hearing impairment (for SM). Vitamin B6 supplementation (50–100 mg daily) is recommended for all patients on INH to mitigate neuropathy.

Clinical Pearls for Practice

• “B6 for INH” — Always prescribe pyridoxine 50–100 mg/day with isoniazid to prevent peripheral neuropathy.

• “RIF’s Induction” — Remember that rifampin induces CYP3A4; adjust dosages of concomitant drugs such as warfarin, oral contraceptives, and protease inhibitors.

• “Optic Check” — Perform baseline and monthly visual acuity and color vision tests while on ethambutol; discontinue if changes occur.

• “PZA & Liver” — Avoid pyrazinamide in patients with severe hepatic impairment; monitor LFTs twice weekly for the first month.

• “Dose Adjustments” — For patients with CrCl <30 mL/min, reduce ethambutol dose by 50%; INH and RIF can be used without adjustment.

• “Pregnancy” — Treat TB as a priority; INH, RIF, and EMB are category B; PZA is category C but may be used if benefits outweigh risks.

• “MDR‑TB” — Incorporate a fluoroquinolone (levofloxacin or moxifloxacin) and a second‑line injectable (amikacin) early to prevent further resistance.

Comparison Table

Exam‑Focused Review

Students preparing for NAPLEX, USMLE Step 2/Step 3, and residency rotations often encounter the following question stems:

• Which first‑line drug is most likely to cause a rash and hepatotoxicity in a patient with a history of alcoholism?

• What is the mechanism of the orange discoloration seen with a common TB medication?

• A 35‑year‑old woman on a TB regimen develops blurred vision; which drug is most likely responsible, and what is the next step?

• Which drug is contraindicated in a patient with severe hepatic failure?

• In a patient with MDR‑TB, which class of drug should be added to the regimen to target dormant bacilli?

Key differentiators:

• INH vs RIF: INH is a prodrug requiring KatG activation and is hepatotoxic; RIF directly inhibits RNA polymerase and is a potent CYP3A4 inducer.

• EMB vs PZA: EMB is bacteriostatic and causes optic neuropathy; PZA is bactericidal against dormant bacilli but can cause hyperuricemia.

• SM vs fluoroquinolones: SM is injectable, ototoxic, nephrotoxic; fluoroquinolones are oral, can prolong QT, and are used in MDR‑TB.

Must‑know facts:

• Standard therapy for drug‑sensitive TB is 2 HRZE + 4 HR.

• Vitamin B6 supplementation is mandatory with INH.

• Rifampin induces CYP3A4, necessitating dose adjustments for many drugs.

• Ethambutol’s toxicity is reversible if detected early; visual acuity should be monitored monthly.

• Pyrazinamide shortens treatment duration but is hepatotoxic; avoid in severe liver disease.

Key Takeaways

1. TB remains a global health priority; early diagnosis and adherence to therapy are essential.

2. First‑line agents target distinct bacterial processes; combination therapy prevents resistance.

3. INH requires pyridoxine supplementation to prevent neuropathy.

4. RIF is a strong CYP3A4 inducer, affecting many concomitant drugs.

5. Ethambutol’s optic toxicity mandates regular visual checks.

6. Pyrazinamide is hepatotoxic and hyperuricemic; monitor liver enzymes closely.

7. Standard regimen for drug‑sensitive TB is 6 months: 2 HRZE + 4 HR.

8. In MDR‑TB, fluoroquinolones and injectable agents are added early.

9. Special populations require dose adjustments and careful monitoring.

10. Adverse effect monitoring and patient education are critical for treatment success.

Always counsel patients that adherence to the full course of therapy is vital to prevent drug resistance and relapse; missing doses can lead to treatment failure and the emergence of multidrug‑resistant TB.